Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000456876 | SCV000541967 | likely benign | Neurofibromatosis, type 1 | 2025-01-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002318496 | SCV000666784 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-08-30 | criteria provided, single submitter | clinical testing | The p.R135Q variant (also known as c.404G>A), located in coding exon 4 of the NF1 gene, results from a G to A substitution at nucleotide position 404. The arginine at codon 135 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Prevention |
RCV000679388 | SCV000806279 | uncertain significance | not provided | 2017-08-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000679388 | SCV001793254 | uncertain significance | not provided | 2020-05-29 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (Lek 2016); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 28481359) |
Genome- |
RCV000456876 | SCV002561453 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing |